Enveric Biosciences, Inc. SEC filings ENVB
Enveric Biosciences, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Jul 30, 2001. Its latest annual report, Form ARS, was filed on Apr 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 14, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEFA14A | Additional proxy material | Apr 14, 2026 | — |
| DEF 14A | Proxy statement | Apr 14, 2026 | Apr 14, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 3, 2026 | Apr 3, 2026 |
| DEF 14A | Proxy statement | Oct 27, 2025 | Oct 27, 2025 |
| PRE 14A | Preliminary proxy statement | Oct 10, 2025 | Oct 10, 2025 |
| DEFA14A | Additional proxy material | Apr 15, 2025 | — |
| DEF 14A | Proxy statement | Apr 15, 2025 | Apr 15, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Dec 18, 2024 | Dec 18, 2024 |
| PRE 14A | Preliminary proxy statement | Nov 27, 2024 | Nov 27, 2024 |
| DEF 14A | Proxy statement | Apr 16, 2024 | Apr 16, 2024 |
| DEFA14A | Additional proxy material | Sep 18, 2023 | — |
| DEF 14A | Proxy statement | Sep 18, 2023 | Sep 18, 2023 |
| PRE 14A | Preliminary proxy statement | Sep 7, 2023 | Sep 7, 2023 |
| DEF 14A | Proxy statement | Sep 23, 2022 | Sep 23, 2022 |
| DEF 14A | Proxy statement | May 31, 2022 | May 31, 2022 |
| PRE 14A | Preliminary proxy statement | May 20, 2022 | May 20, 2022 |
| DEF 14A | Proxy statement | Apr 13, 2021 | Apr 13, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 19, 2021 | Mar 19, 2021 |
| DEF 14A | Proxy statement | Nov 4, 2020 | Nov 4, 2020 |
| DEFA14A | Additional proxy material | Oct 30, 2019 | — |
| DEF 14A | Proxy statement | Sep 27, 2019 | Oct 29, 2019 |
| PRE 14A | Preliminary proxy statement | Aug 23, 2019 | Aug 22, 2019 |
| DEF 14A | Proxy statement | Aug 22, 2018 | Aug 10, 2018 |
| PRE 14A | Preliminary proxy statement | Aug 10, 2018 | Aug 10, 2018 |
| DEF 14A | Proxy statement | Jul 16, 2018 | Jun 29, 2018 |
| PRE 14A | Preliminary proxy statement | Jul 2, 2018 | Jun 29, 2018 |
| DEF 14A | Proxy statement | May 20, 2016 | May 2, 2016 |
| PRE 14A | Preliminary proxy statement | May 4, 2016 | May 2, 2016 |
| DEF 14C | Information statement | May 6, 2015 | May 5, 2015 |
| PRE 14C | Filing | Apr 24, 2015 | Apr 20, 2015 |
| DEFA14A | Additional proxy material | May 31, 2007 | — |
| DEFM14A | Definitive proxy statement | May 15, 2007 | — |
| PREM14A | Preliminary proxy statement | May 3, 2007 | — |
| DEFA14A | Additional proxy material | Jan 9, 2007 | — |
| DEFM14A | Form defm14a | Nov 30, 2006 | — |
| PREM14A | Form prem14a | Oct 17, 2006 | — |
| DEF 14A | Proxy statement | Apr 22, 2005 | Jun 17, 2005 |
| DEF 14A | Proxy statement | Apr 27, 2004 | Jun 11, 2004 |
| DEF 14A | Proxy statement | Apr 30, 2003 | Jun 13, 2003 |
| DEF 14A | Proxy statement | Apr 30, 2002 | Jun 14, 2002 |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENVB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 890821
- Former names
- AMERI Holdings, Inc. (until Dec 30, 2020); SPATIALIZER AUDIO LABORATORIES INC (until May 27, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.